QuVa Pharma Announces Its Ability to Supply Hydromorphone and Morphine Pre-Filled Syringes

-- Compounded Hydromorphone and Morphine syringes are expected to help alleviate drug shortages impacting the nation's hospitals --

News provided by

QuVa Pharma, Inc.

Nov 21, 2017, 08:03 ET

HOUSTON, Nov. 21, 2017 /PRNewswire/ -- There is a nation-wide shortage of pre-filled syringe presentations of hydromorphone and morphine. This shortage is expected to persist for a number of months.

QuVa Pharma, Inc. is pleased to announce that it has available supplies of:

Hydromorphone 1mg/ml in 1ml 0.9% Sodium Chloride in a 3ml syringe

Hydromorphone 2mg/ml in 1ml 0.9% Sodium Chloride in a 3ml syringe

Morphine 2mg/ml in 1ml 0.9% Sodium Chloride in a 3ml syringe

Morphine 4mg/ml in 1ml 0.9% Sodium Chloride in a 3ml syringe

QuVa Pharma is currently supplying these products to existing customers and welcomes new inquiries.

With deep aseptic pharmaceutical manufacturing experience, QuVa Pharma specializes in critical drug shortage products. The hydromorphone and morphine compounded by QuVa Pharma is sourced from a USA made and FDA approved manufacturer, and joins a range of critical shortage products including Dextrose 25 & 50, Potassium Chloride, Fentanyl, Labetalol, Lorazepam and Rocuronium all compounded from FDA approved starting material. All product sold is accompanied by a Certificate of Analysis verifying sterility, and product specifications.

"With increasing numbers of sterile product drug shortages, it is important that we are able to offer high quality solutions for our customers and provide reliable, pertinent, and cost-effective product for them to continue quality care to their patients," said Stuart Hinchen, QuVa Pharma's co-founder and Chief Executive Officer. "We are able to maintain the industry leading quality standards of our products by only sourcing product from FDA approved suppliers of the starting material and following cGMP standards. This lifts the burden off the hospitals to find their own solutions without the same level of supplier knowledge and product development controls that we have. Patients need solutions in drug shortage situations, and we aim to be there for them."

QuVa Pharma is the market leader in quality compliance with both existing Texas facilities in excellent standing with the FDA, having received the Inspection Close out report in March 2017 for the main Sugar Land, Texas campus and also for its Temple, Texas facility in July 2017. QuVa Pharma has opened the first phase of its 160,000 sq. ft. New Jersey facility.

For product ordering inquiries please contact QuVa Pharma Customer Service at 888.339.0874 or via email

[email protected].

About QuVa Pharma, Inc.

QuVa Pharma is a nationally recognized company emerging as the leading industry 503B platform and partner of choice for compliance-oriented healthcare facilities looking to ensure a quality, safe and consistent supply of medications. The Company offers a broad portfolio of products across Pain Management, Anti-infective, OR Syringes, Labor and Delivery therapeutic areas amongst others, all of which are released only once sterility and potency testing is successfully complete, and with validation supporting appropriate BUD. The company is committed to having a patient-first orientation, as well as a robust product portfolio, leading safety standards, and collaborative, partnership-oriented customer service. For more information, visit www.quvapharma.com.

CONTACT: Peter Jenkins, 1-973-775-2673, [email protected]

SOURCE QuVa Pharma, Inc.